Chairman of the Board, ConcentRx, Inc.
Dr. Sohn has deep industry knowledge with thirty years of U.S. and global experience in the pharmaceutical industry, and a reputation as a strategic thinker with the ability to drive a strong interface between research and development and marketing. She was named ‘Woman of the Year’ by the Healthcare Businesswomen’s Association in 2003, ‘Distinguished Alumnus’ by University of California San Francisco (2000) and has received the Licensing Executive Society’s ‘Frank Barnes Mentoring Award’ (2009) and the HBA Euro-Excellence Award (2012). Her areas of expertise include domestic and global business development, strategy and product marketing/launch execution across vaccines, pharmaceutical products and consumer healthcare brands, having led the launches of the U.S. Vaccine Business and a $1 billion CNS pharmaceutical product at SmithKline Beecham (now GlaxoSmithKline). From 1998 to 2010, Dr. Sohn was Senior Vice President for Worldwide Business Development for GlaxoSmithKline’s $6 billion Consumer Healthcare division where she served on the Global Executive Committee and led numerous US, global, European and Japanese transactions and integrations. In the pharmaceutical division, from 1994 to 1998, she was Vice President, Worldwide Strategic Product Development at SmithKline Beecham for the Cardiovascular, Pulmonary, and Metabolic Therapeutic Areas with responsibility for product strategy, valuation and strategic commercial leadership of all assets from Phase 1 through life cycle management. She has a strong technical background, having begun her career in anti-infective medical affairs at SmithKline & French in 1982. Dr. Sohn received a Doctor of Pharmacy degree from the University of California San Francisco, a Certificate of Professional Development from The Wharton School at the University of Pennsylvania, is a Board Leadership Fellow of the National Association of Corporate Directors (NACD), and is a Certified Licensing Professional. Dr. Sohn is an independent Director on the Board of Directors of Jazz Pharmaceuticals plc (JAZZ), Landec Corporation (LNDC), and Neuralstem, Inc (CUR), all publicly-traded life science companies.